Report an efficacy greater than 92% of the Cuban vaccine candidate – Telam

The announcement comes at a time when the island is experiencing a strong outbreak of the disease.

The Cuban-made Abdala coronavirus vaccine candidate has over 92% effectiveness, BioCubaFarma, the laboratory that developed what is set to become the first Covid-19 vaccine created in Monday, reported Monday. Latin America. .

“@CIGBCuba’s #Abdala vaccine candidate shows 92.28% efficacy, in its 3-dose regimen. #CubaEsCiencia,” the lab said in a Twitter message, AFP news agency reported.

The announcement comes just two days after scientific authorities announced that Soberana 2, Cuba’s other vaccine candidate, which has also completed its three phases of testing, achieved 62% efficacy with two doses, on three which are considering vaccines developed on the Island.

The World Health Organization (WHO) requires at least 50% efficacy for a candidate to be accepted as a vaccine.

Cuban authorities have announced that in a few weeks they plan to ask the regulatory authority for permission to use the vaccines on an emergency basis, AFP added.

The announcement comes at a time when the island is experiencing a strong outbreak of the disease: it recorded this Monday one of its worst days with 1,561 positive cases, while since the start of the pandemic there are 169,365 infections and 1,170 deaths.

Under an American embargo since 1962, Cuba began to develop its own remedies in the 1980s. Of the 13 vaccines in its vaccination program, eight are produced locally.